Increased  ||| S:0 E:10 ||| JJ
use  ||| S:10 E:14 ||| NN
of  ||| S:14 E:17 ||| IN
community  ||| S:17 E:27 ||| NN
medicine  ||| S:27 E:36 ||| NN
distributors  ||| S:36 E:49 ||| NNS
and  ||| S:49 E:53 ||| CC
rational  ||| S:53 E:62 ||| JJ
use  ||| S:62 E:66 ||| NN
of  ||| S:66 E:69 ||| IN
drugs  ||| S:69 E:75 ||| NNS
in  ||| S:75 E:78 ||| IN
children  ||| S:78 E:87 ||| NNS
less  ||| S:87 E:92 ||| RBR
than  ||| S:92 E:97 ||| IN
five  ||| S:97 E:102 ||| CD
years  ||| S:102 E:108 ||| NNS
of  ||| S:108 E:111 ||| IN
age  ||| S:111 E:115 ||| NN
in  ||| S:115 E:118 ||| IN
Uganda  ||| S:118 E:125 ||| NNP
caused  ||| S:125 E:132 ||| VBD
by  ||| S:132 E:135 ||| IN
integrated  ||| S:135 E:146 ||| JJ
community  ||| S:146 E:156 ||| NN
case  ||| S:156 E:161 ||| NN
management  ||| S:161 E:172 ||| NN
of  ||| S:172 E:175 ||| IN
fever  ||| S:175 E:181 ||| NN
We  ||| S:181 E:184 ||| PRP
compared  ||| S:184 E:193 ||| VBN
use  ||| S:193 E:197 ||| NN
of  ||| S:197 E:200 ||| IN
community  ||| S:200 E:210 ||| NN
medicine  ||| S:210 E:219 ||| NN
distributors  ||| S:219 E:232 ||| NNS
( ||| S:232 E:233 ||| -LRB-
CMDs ||| S:233 E:237 ||| NNP
)  ||| S:237 E:239 ||| -RRB-
and  ||| S:239 E:243 ||| CC
drug  ||| S:243 E:248 ||| NN
use  ||| S:248 E:252 ||| NN
under  ||| S:252 E:258 ||| IN
integrated  ||| S:258 E:269 ||| JJ
community  ||| S:269 E:279 ||| NN
case  ||| S:279 E:284 ||| NN
management  ||| S:284 E:295 ||| NN
and  ||| S:295 E:299 ||| CC
home-based  ||| S:299 E:310 ||| JJ
management  ||| S:310 E:321 ||| NN
strategies  ||| S:321 E:332 ||| NNS
in  ||| S:332 E:335 ||| IN
children  ||| S:335 E:344 ||| NNS
6-59  ||| S:344 E:349 ||| CD
months  ||| S:349 E:356 ||| NNS
of  ||| S:356 E:359 ||| IN
age  ||| S:359 E:363 ||| NN
in  ||| S:363 E:366 ||| IN
eastern  ||| S:366 E:374 ||| JJ
Uganda ||| S:374 E:380 ||| NNP
.  ||| S:380 E:382 ||| .
A  ||| S:382 E:384 ||| DT
cross-sectional  ||| S:384 E:400 ||| JJ
study  ||| S:400 E:406 ||| NN
with  ||| S:406 E:411 ||| IN
1,095  ||| S:411 E:417 ||| CD
children  ||| S:417 E:426 ||| NNS
was  ||| S:426 E:430 ||| VBD
nested  ||| S:430 E:437 ||| VBN
in  ||| S:437 E:440 ||| IN
a  ||| S:440 E:442 ||| DT
cluster  ||| S:442 E:450 ||| JJ
randomized  ||| S:450 E:461 ||| JJ
trial  ||| S:461 E:467 ||| NN
with  ||| S:467 E:472 ||| IN
integrated  ||| S:472 E:483 ||| JJ
community  ||| S:483 E:493 ||| NN
case  ||| S:493 E:498 ||| NN
management  ||| S:498 E:509 ||| NN
( ||| S:509 E:510 ||| -LRB-
CMDs  ||| S:510 E:515 ||| JJ
treating  ||| S:515 E:524 ||| JJ
malaria  ||| S:524 E:532 ||| NN
and  ||| S:532 E:536 ||| CC
pneumonia ||| S:536 E:545 ||| CD
)  ||| S:545 E:547 ||| -RRB-
as  ||| S:547 E:550 ||| IN
the  ||| S:550 E:554 ||| DT
intervention  ||| S:554 E:567 ||| NN
and  ||| S:567 E:571 ||| CC
home-based  ||| S:571 E:582 ||| JJ
management  ||| S:582 E:593 ||| NN
( ||| S:593 E:594 ||| -LRB-
CMDs  ||| S:594 E:599 ||| JJ
treating  ||| S:599 E:608 ||| VBG
only  ||| S:608 E:613 ||| RB
malaria ||| S:613 E:620 ||| CD
)  ||| S:620 E:622 ||| -RRB-
as  ||| S:622 E:625 ||| IN
the  ||| S:625 E:629 ||| DT
control ||| S:629 E:636 ||| NN
.  ||| S:636 E:638 ||| .
Care-seeking  ||| S:638 E:651 ||| JJ
from  ||| S:651 E:656 ||| IN
CMDs  ||| S:656 E:661 ||| NNP
was  ||| S:661 E:665 ||| VBD
higher  ||| S:665 E:672 ||| JJR
in  ||| S:672 E:675 ||| IN
intervention  ||| S:675 E:688 ||| NN
areas  ||| S:688 E:694 ||| NNS
( ||| S:694 E:695 ||| -LRB-
31 ||| S:695 E:697 ||| CD
% ||| S:697 E:698 ||| NN
)  ||| S:698 E:700 ||| -RRB-
than  ||| S:700 E:705 ||| IN
in  ||| S:705 E:708 ||| IN
control  ||| S:708 E:716 ||| NN
areas  ||| S:716 E:722 ||| NNS
( ||| S:722 E:723 ||| -LRB-
22 ||| S:723 E:725 ||| CD
% ||| S:725 E:726 ||| NN
;  ||| S:726 E:728 ||| :
P  ||| S:728 E:730 ||| NN
=  ||| S:730 E:732 ||| SYM
0.01 ||| S:732 E:736 ||| CD
) ||| S:736 E:737 ||| -RRB-
.  ||| S:737 E:739 ||| .
Prompt  ||| S:739 E:746 ||| NNP
and  ||| S:746 E:750 ||| CC
appropriate  ||| S:750 E:762 ||| JJ
treatment  ||| S:762 E:772 ||| NN
of  ||| S:772 E:775 ||| IN
malaria  ||| S:775 E:783 ||| NN
was  ||| S:783 E:787 ||| VBD
higher  ||| S:787 E:794 ||| JJR
in  ||| S:794 E:797 ||| IN
intervention  ||| S:797 E:810 ||| NN
areas  ||| S:810 E:816 ||| NNS
( ||| S:816 E:817 ||| -LRB-
18 ||| S:817 E:819 ||| CD
% ||| S:819 E:820 ||| NN
)  ||| S:820 E:822 ||| -RRB-
than  ||| S:822 E:827 ||| IN
in  ||| S:827 E:830 ||| IN
control  ||| S:830 E:838 ||| NN
areas  ||| S:838 E:844 ||| NNS
( ||| S:844 E:845 ||| -LRB-
12 ||| S:845 E:847 ||| CD
% ||| S:847 E:848 ||| NN
;  ||| S:848 E:850 ||| :
P  ||| S:850 E:852 ||| NN
=  ||| S:852 E:854 ||| SYM
0.03 ||| S:854 E:858 ||| CD
)  ||| S:858 E:860 ||| -RRB-
and  ||| S:860 E:864 ||| CC
among  ||| S:864 E:870 ||| IN
CMD  ||| S:870 E:874 ||| NNP
users  ||| S:874 E:880 ||| NNS
( ||| S:880 E:881 ||| -LRB-
37 ||| S:881 E:883 ||| CD
% ||| S:883 E:884 ||| NN
)  ||| S:884 E:886 ||| -RRB-
than  ||| S:886 E:891 ||| IN
other  ||| S:891 E:897 ||| JJ
health  ||| S:897 E:904 ||| NN
providers  ||| S:904 E:914 ||| NNS
( ||| S:914 E:915 ||| -LRB-
9 ||| S:915 E:916 ||| CD
% ||| S:916 E:917 ||| NN
) ||| S:917 E:918 ||| -RRB-
.  ||| S:918 E:920 ||| .
The  ||| S:920 E:924 ||| DT
mean  ||| S:924 E:929 ||| JJ
number  ||| S:929 E:936 ||| NN
of  ||| S:936 E:939 ||| IN
drugs  ||| S:939 E:945 ||| NNS
among  ||| S:945 E:951 ||| IN
CMD  ||| S:951 E:955 ||| NNP
users  ||| S:955 E:961 ||| NNS
compared  ||| S:961 E:970 ||| VBN
with  ||| S:970 E:975 ||| IN
other  ||| S:975 E:981 ||| JJ
health  ||| S:981 E:988 ||| NN
providers  ||| S:988 E:998 ||| NNS
was  ||| S:998 E:1002 ||| VBD
1.6  ||| S:1002 E:1006 ||| CD
versus  ||| S:1006 E:1013 ||| CD
2.4  ||| S:1013 E:1017 ||| CD
in  ||| S:1017 E:1020 ||| IN
intervention  ||| S:1020 E:1033 ||| NN
areas  ||| S:1033 E:1039 ||| NNS
and  ||| S:1039 E:1043 ||| CC
1.4  ||| S:1043 E:1047 ||| CD
versus  ||| S:1047 E:1054 ||| CD
2.3  ||| S:1054 E:1058 ||| CD
in  ||| S:1058 E:1061 ||| IN
control  ||| S:1061 E:1069 ||| NN
areas ||| S:1069 E:1074 ||| NNS
.  ||| S:1074 E:1076 ||| .
Use  ||| S:1076 E:1080 ||| NN
of  ||| S:1080 E:1083 ||| IN
CMDs  ||| S:1083 E:1088 ||| NNP
was  ||| S:1088 E:1092 ||| VBD
low ||| S:1092 E:1095 ||| JJ
.  ||| S:1095 E:1097 ||| .
However ||| S:1097 E:1104 ||| RB
,  ||| S:1104 E:1106 ||| ,
integrated  ||| S:1106 E:1117 ||| JJ
community  ||| S:1117 E:1127 ||| NN
case  ||| S:1127 E:1132 ||| NN
management  ||| S:1132 E:1143 ||| NN
of  ||| S:1143 E:1146 ||| IN
childhood  ||| S:1146 E:1156 ||| NN
illnesses  ||| S:1156 E:1166 ||| NNS
increased  ||| S:1166 E:1176 ||| VBD
use  ||| S:1176 E:1180 ||| NN
of  ||| S:1180 E:1183 ||| IN
CMDs  ||| S:1183 E:1188 ||| JJ
and  ||| S:1188 E:1192 ||| CC
rational  ||| S:1192 E:1201 ||| JJ
drug  ||| S:1201 E:1206 ||| NN
use ||| S:1206 E:1209 ||| NN
.  ||| S:1209 E:1211 ||| .
